Purpose: A 28-day US study in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
24
Matching placebo of 100 mg BID
INCB013739 100 mg BID
Unnamed facility
Chula Vista, California, United States
Unnamed facility
The Bronx, New York, United States
Unnamed facility
San Antonio, Texas, United States
Changes in lipid profile laboratory values
Time frame: Measured at baseline and weekly for four weeks
Assessment of pharmacokinetics of INCB013739 through analysis of blood samples.
Time frame: Measured at baseline and weekly for four weeks
Assessment of pharmacodynamics of INCB013739 through analysis of blood samples
Time frame: Measured at baseline and weekly for four weeks
Assessment of ECGs, physical examinations and laboratory values for adverse events
Time frame: Measured at baseline through study completion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.